Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs

American Journal of Veterinary Research

Volumn 66, Issue 12, 2005, Pages 2172-2176

  Arsenault, Wendy G ^a,b   Boothe, Dawn M ^a,c   Gordon, Sonya G ^a   Miller, Matthew W ^a   Chalkley, Jeffrey R ^a,d   Petrikovics, Ilona ^a,c  

^a TEXAS A AND M UNIVERSITY   (United States)

^b Southwest Florida Veterinary Cardiology   (United States)

^c AUBURN UNIVERSITY   (United States)

^d KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL;

ANIMAL EXPERIMENT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD SAMPLING; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEAN RESIDENCE TIME; NONHUMAN; STEADY STATE;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARBAZOLES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOGS; INJECTIONS, INTRAVENOUS; PROPANOLAMINES; TIME FACTORS;

ANIMALIA; CANIS FAMILIARIS;

EID: 33645241083     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.2172     Document Type: Article

References (13)

1. Lechat P, Packer M, Chalon S, et al. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-1191.
2. Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol 2000;36:2081-2089.
3. Tsutsui H, Spinale FG, Nagatsu M, et al. Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994;93:2639-2648.
4. Das KM, Tashjian RJ. Chronic mitral valve disease in the dog. Vet Med Small Anim Clin 1965;60:1209-1216.
5. Detweiler DK, Patterson DF. The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci 1965;127:481-516.
6. Gordon SG, Arsenault WG, Longnecker M, et al. Pharmacodynanics of carvedilol in conscious, healthy dogs. J Vet Intern Med 2006;in press.
7. Hokama N, Hobara N, Kameya H, et al. Rapid and simple micro-determination of carvedilol in rat plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999;732:233-238.
8. Sawangkoon S, Miyamoto M, Nakayama T, et al. Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. Am J Vet Res 2000;61:57-60.
9. Uechi M, Sasaki T, Ueno K, et al. Cardiovascular and renal effects of carvedilol in dogs with heart failure. J Vet Med Sci 2002;64:469-475.
10. McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy Drugs 1993;45:232-258.
11. Neugebauer G, Akpan W, von Mollendorff E, et al. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987;10:S85-S88.
12. Coreg [product monograph]. Mississauga, ON, Canada: SmithKline Beecham Pharma Inc, 1996.
13. Schaefer WM, Politowski J, Hwang B, et al. Metabolism of carvedilol in dogs, rats, and mice. Drug Metab Dispos 1998;26:958-969.